Isometric diagram of a glowing teal folded growth-factor analog with highlighted amber modification regions beside faint unbound binding-protein shapes, representing a modified growth-factor analog
Mindful Research

IGF-1 LR3: A Modified Growth-Factor Analog In Vitro

Updated By: Mindful Research Team1 min read

Key takeaways

  • IGF-1 LR3 is a synthetic modified analog of insulin-like growth factor 1 (IGF-1).
  • The LR3 modifications change how it interacts with binding proteins.
  • That alters its availability in a cell-based system vs the unmodified growth factor.
  • Studied in vitro with receptor-activation and downstream-signaling assays.
  • Supplied as a research material for in vitro research use only.

IGF-1 LR3 is a modified analog of a growth factor, engineered with sequence changes that alter its binding behavior, and it is studied in vitro as a research material. This profile describes the compound and its study.

What is IGF-1 LR3?

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1), carrying sequence modifications. It is described here only by structure and molecular target, as a laboratory material.

What the modification does

The "LR3" modifications change how the analog interacts with binding proteins, which alters its availability in a cell-based system compared with the unmodified growth factor. This is a chemistry-level distinction studied in vitro.

How it is studied in vitro

Researchers use cell-based assays that read out receptor activation and downstream signaling, comparing the analog with reference conditions under controlled settings.

Why modified analogs are studied

A modified analog is a tool for probing how specific sequence changes affect receptor interaction and signaling in a defined system.

Related research guides

Research-use note

IGF-1 LR3 is supplied as a research material for in vitro research use only. It is not for human or animal use.

Related research: IGF-1 LR3.

Frequently asked questions

What is IGF-1 LR3?

A synthetic modified analog of insulin-like growth factor 1 (IGF-1) carrying sequence changes, studied in vitro as a laboratory material. View IGF-1 LR3

What do the LR3 modifications do?

They change how the analog interacts with binding proteins, altering its availability in a cell-based system compared with the unmodified growth factor.

How is it studied in vitro?

With cell-based assays reading out receptor activation and downstream signaling, compared with reference conditions.

Why study modified analogs?

To probe how specific sequence changes affect receptor interaction and signaling in a defined system.

Research use only?

Yes, in vitro laboratory research use only.

Continue reading

Vial of blue copper-complex lyophilized peptide powder in a cold-storage block, representing KLOW 80 mg handling and stabilityKLOW 80 mg: Copper-Complex Blue Lyophilized Powder, Handling, Stability and Stock Concentration Math The KLOW 80 mg vial is a pale-blue lyophilized powder because one of its four components, GHK-Cu, is a copper(II) complex; reconstituted... Researcher in a lab coat checking a vial of blue peptide blend powder against a four-peak analytical readoutSourcing KLOW as a Research Material: Per-Component COA and Purity Sourcing KLOW as a research material means obtaining, in one Certificate of Analysis, the identity and purity data for all four of... Two vials of blue peptide blend powder side by side, one with an extra tripeptide render, representing GLOW versus KLOWGLOW vs KLOW: What KPV Adds to the Blend (Composition Comparison) The difference between GLOW and KLOW is one component: KLOW adds 10 mg of the tripeptide KPV (Lys-Pro-Val, CAS 67727-97-3) to GLOW's...